januari
new
coronaviru
offici
name
implic
alarm
outbreak
pneumonialik
ill
origin
wuhan
citi
hubei
china
humantohuman
transmiss
first
confirm
guangdong
china
world
health
organis
declar
global
public
health
emerg
februari
confirm
case
report
death
toll
height
crisi
viru
spread
rate
scale
far
wors
previou
coronavir
epidem
immedi
evid
genom
coronaviru
evolutionarili
relat
ident
betacoronaviru
implic
sever
acut
respiratori
syndrom
sar
origin
bat
caus
global
outbreak
momentum
research
develop
antivir
agent
sarscov
carri
epidem
subsid
despit
sar
treatment
yet
come
fruition
howev
knowledg
acquir
extens
research
develop
effort
may
use
inform
current
therapeut
option
viral
genom
encod
protein
among
two
proteas
pl
pro
pro
vital
viru
replic
cleav
two
translat
polyprotein
individu
function
compon
proteas
pro
aka
main
proteas
pro
consid
promis
drug
target
tremend
effort
spent
studi
protein
order
identifi
therapeut
sarscov
particular
pathogen
coronavirus
eg
merscov
middl
east
respiratori
syndrom
coronaviru
gener
share
similar
activ
site
enzymat
mechan
purpos
studi
build
molecular
model
pro
carri
virtual
screen
identifi
readili
usabl
therapeut
intent
howev
comment
structurebas
drug
design
research
time
current
epidem
translat
polyprotein
sequenc
obtain
annot
genbank
entri
genom
access
number
compar
sequenc
sarscov
sequenc
access
number
proteas
cleavag
site
matur
protein
sequenc
obtain
sequenc
comparison
align
perform
blastp
highresolut
apoenzym
structur
sarscov
pro
pdbid
employ
templat
variant
residu
mutat
silico
follow
manual
adjust
ensur
best
sidechain
rotam
employ
tabl
rebuilt
model
subject
steepest
descent
energi
minimis
gromac
use
gromo
forcefield
restraint
forc
constant
kj
mol
nm
appli
backbon
atom
atom
vital
residu
tabl
access
surfac
area
residu
calcul
areaimol
suit
mtiopenscreen
web
servic
use
screen
librari
purchas
drug
drugslib
bind
site
grid
specifi
activesit
residu
activ
site
chain
chain
b
screen
independ
autodock
vina
crystal
structur
releas
strip
inhibitor
subject
screen
list
target
ligand
dock
combin
rank
bind
energi
produc
screen
top
rank
use
bind
energi
cutoff
hit
chain
b
examin
visual
pymol
version
earlier
version
articl
found
chemrxiv
doi
first
avail
genom
genbank
ncbi
refer
sequenc
sequenc
extract
align
sarscov
overal
aminoacid
sequenc
ident
high
conserv
notic
polyprotein
cleavag
site
pro
site
highli
conserv
ident
extend
data
tabl
infer
respect
proteas
similar
specif
pro
sequenc
residu
differ
sarscov
ident
compar
polyprotein
pro
sequenc
among
genom
genbank
avail
februari
refer
among
residu
one
variabl
residu
two
remain
five
differ
summaris
pro
sequenc
cleavag
junction
polyprotein
conserv
amino
acid
known
import
enzym
function
list
tabl
unexpectedli
none
variant
posit
involv
major
role
therefor
confid
prepar
structur
model
pro
molecular
model
extend
data
figur
immedi
use
silico
develop
target
treatment
submit
first
draft
studi
crystal
structur
pro
solv
releas
pdb
id
confirm
predict
model
good
within
experiment
error
extend
data
figur
examin
molecular
graphic
solut
found
fit
respect
activ
site
convincingli
bind
energi
chain
complex
gener
higher
chain
b
approxim
kcal
mol
tabl
presum
demonstr
intrins
conform
variabl
bchain
activ
site
crystal
structur
averag
rootmeansquar
deviat
rmsd
atom
posit
activesit
residu
screen
differ
bind
energi
small
suggest
rank
discriminatori
top
scorer
examin
combin
two
screen
found
candid
give
promis
bind
model
etoposid
phosphat
count
one
tabl
check
action
target
side
effect
candid
among
first
notic
velpatasvir
figur
ledipasvir
inhibitor
protein
hepat
c
viru
hcv
market
approv
drug
combin
sofosbuvir
prodrug
nucleotid
analogu
inhibitor
rnadepend
rna
polymeras
rdrp
interestingli
sofosbuvir
recent
propos
antivir
base
similar
replic
mechan
hcv
coronavirus
result
strengthen
dualcompon
hcv
drug
epclusa
velpatasvirsofosbuvir
harvoni
ledipasvirsofosbuvir
may
attract
candid
repurpos
may
inhibit
two
coronavir
enzym
drug
target
two
viral
protein
substanti
reduc
abil
viru
develop
resist
directact
antivir
drug
also
associ
minim
side
effect
conveni
oral
administ
tabl
flavonoid
glycosid
diosmin
figur
hesperidin
figur
obtain
citru
fruit
fit
well
block
substrat
bind
site
yet
compound
caus
mild
advers
reaction
tabl
hesperidin
hit
show
multipl
time
suggest
mani
mode
bind
figur
teniposid
etoposid
phosphat
chemic
relat
turn
multipl
hit
good
bind
model
figur
howev
chemotherapi
drug
lot
strong
side
effect
need
intraven
administr
tabl
approv
drug
venetoclax
figur
investig
drug
score
well
screen
venetoclax
anoth
chemotherapi
drug
burden
side
effect
includ
upper
respiratori
tract
infect
tabl
much
disclos
subject
crystal
structur
virtual
screen
procedur
similar
list
candid
show
consist
extend
data
tabl
high
score
although
ledipasvir
found
notic
compound
list
molecular
weight
mw
except
lumacaftor
largest
one
ledipasvir
size
peptid
substrat
deepli
buri
proteas
activ
site
demand
larg
molecul
mani
rotat
dynam
fit
identifi
five
trial
clinicaltrialsgov
involv
antivir
immunomodulatori
drug
treatment
sar
tabl
without
report
result
ie
present
safe
effect
drug
candid
sarscov
epidem
patient
recruit
clinic
trial
studi
streptokinas
succeed
complet
phase
disappoint
littl
progress
sar
drug
develop
made
past
year
outbreak
numer
inhibitor
pro
enzym
propos
yet
new
drug
candid
succeed
enter
clinic
phase
one
record
receiv
lot
attent
amid
current
outbreak
lopinavirritonavir
combin
proteas
inhibitor
origin
develop
hiv
sar
outbreak
despit
lack
clinic
trial
tri
emerg
measur
found
offer
improv
clinic
outcom
howev
scientist
express
sceptic
analog
compound
specul
act
sarscov
pro
specif
yet
crystal
structur
support
although
dock
studi
carri
propos
variou
bind
mode
ic
valu
lopinavir
k
ritonavir
establish
although
far
cure
base
result
two
cov
pro
enzym
ident
far
protein
sequenc
substrat
specif
concern
opinion
still
one
recommend
rout
immedi
treatment
time
write
earli
februari
look
beyond
pro
earlier
screen
produc
candid
could
repurpos
sarscov
merscov
addit
coronavir
protein
could
target
screen
treatment
remdesivir
repurpos
drug
develop
target
rdrp
show
improv
clinic
outcom
report
clinic
trial
underway
consid
work
part
global
effort
respond
time
fashion
fight
deadli
communic
diseas
awar
similar
model
screen
repurpos
exercis
target
pro
report
announc
method
overlap
share
common
result
studi
polyprotein
pro
sequenc
use
studi
obtain
ncbi
genbank
access
number
avail
februari
sarscov
sequenc
wsa
obtain
ncbi
protein
access
number
two
coronaviru
proteas
structur
use
obtain
protein
data
bank
id
open
scienc
framework
model
screen
http
virtual
screen
folder
contain
follow
extend
data
extend
result
folder
contain
follow
extend
data
data
avail
term
creativ
common
zero
right
reserv
data
waiver
public
domain
dedic
